

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM S-8  
REGISTRATION STATEMENT**  
*UNDER  
THE SECURITIES ACT OF 1933*

---

**Corvus Pharmaceuticals, Inc.**

(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**46-4670809**  
(I.R.S. Employer  
Identification Number)

**863 Mitten Road, Suite 102  
Burlingame, CA 94010  
(650) 900-4520**

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

**2016 Equity Incentive Award Plan**  
(Full Title of the Plan)

**Richard A. Miller, M.D.  
President and Chief Executive Officer  
Corvus Pharmaceuticals, Inc.  
863 Mitten Road, Suite 102  
Burlingame, CA 94010  
(650) 900-4520**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copies to:*

**Phillip S. Stoup, Esq.  
Latham & Watkins LLP  
140 Scott Drive  
Menlo Park, CA 94025  
Telephone: (650) 328-4600  
Facsimile: (650) 463-2600**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

**Proposed sale to take place as soon after the effective date of the  
registration statement as awards under the plans are exercised and/or vest.**

---

---

---

## EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,862,000 shares of the Registrant's common stock issuable under the 2016 Equity Incentive Plan, for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933, 333-255614 and 333-264718) are effective, as a result of the operation of an automatic annual increase provision therein.

### INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on [March 29, 2016](#), [March 10, 2017](#), [March 13, 2018](#), [May 9, 2019](#), [April 30, 2020](#), [April 29, 2021](#) and [May 5, 2022](#) (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933, 333-255614 and 333-264718) are incorporated by reference herein.

## Exhibit Index

Exhibit Number	Exhibit Description	Incorporated by Reference			Filed Herewith
		Form	Date	Number	
4.1	<a href="#">Amended and Restated Certificate of Incorporation.</a>	8-K	3/29/2016	3.1	
4.2	<a href="#">Amended and Restated Bylaws.</a>	8-K	3/29/2016	3.2	
4.3	<a href="#">Form of Common Stock Certificate.</a>	S-1	1/4/2016	4.2	
4.4	<a href="#">Amended and Restated Investors' Rights Agreement, dated September 16, 2015, by and among Corvus Pharmaceuticals, Inc. and the investors listed therein.</a>	S-1/A	2/8/2016	4.3	
5.1	<a href="#">Opinion of Latham &amp; Watkins LLP.</a>				X
23.1	<a href="#">Consent of independent registered public accounting firm.</a>				X
23.2	<a href="#">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</a>				X
24.1	<a href="#">Power of Attorney. Reference is made to the signature page to the Registration Statement.</a>				X
99.2(a)#	<a href="#">2016 Equity Incentive Award Plan.</a>	S-8	3/29/2016	99.2(a)	
99.2(b)#	<a href="#">Form of Stock Option Grant Notice and Stock Option Agreement under the 2016 Equity Incentive Award Plan.</a>	S-1	1/4/2016	10.5(b)	
99.2(c)#	<a href="#">Form of Restricted Stock Award Agreement and Restricted Stock Unit Award Agreement under the 2016 Equity Incentive Award Plan.</a>	S-1	1/4/2016	10.5(c)	
99.2(d)#	<a href="#">Form of Restricted Stock Unit Award Agreement and Restricted Stock Unit Award Grant Notice under the 2016 Equity Incentive Award Plan.</a>	S-1	1/4/2016	10.5(d)	
107.1	<a href="#">Calculation of Filing Fee Table</a>				X

# Indicates management contract or compensatory plan.



140 Scott Drive  
 Menlo Park, California 94025  
 Tel: +1.650.328.4600 Fax: +1.650.463.2600  
 www.lw.com

**LATHAM & WATKINS** LLP

FIRM / AFFILIATE OFFICES

Austin	Milan
Beijing	Munich
Boston	New York
Brussels	Orange County
Century City	Paris
Chicago	Riyadh
Dubai	San Diego
Düsseldorf	San Francisco
Frankfurt	Seoul
Hamburg	Shanghai
Hong Kong	Silicon Valley
Houston	Singapore
London	Tel Aviv
Los Angeles	Tokyo
Madrid	Washington, D.C.

March 28, 2023

Corvus Pharmaceuticals, Inc.  
 863 Mitten Road, Suite 102  
 Burlingame, CA 94010

Re: Registration Statement on Form S-8; 1,862,000 shares of Common Stock of Corvus Pharmaceuticals, Inc., par value \$0.0001 per share

To the addressee set forth above:

We have acted as special counsel to Corvus Pharmaceuticals, Inc., a Delaware corporation (the “*Company*”), in connection with the registration by the Company of an aggregate of 1,862,000 shares of common stock of the Company, par value \$0.0001 per share (the “*Common Stock*”) (the “*Shares*”) issuable under the 2016 Equity Incentive Award Plan (the “*Plan*”).

The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the “*Act*”), filed with the Securities and Exchange Commission (the “*Commission*”) on March 28, 2023 (the “*Registration Statement*”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the prospectus forming a part thereof, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “*DGCL*”), and we express no opinion with respect to any other laws.

**LATHAM & WATKINS**<sup>LLP</sup>

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Plan, assuming in each case that the individual issuances, grants or awards under the Plan are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Sincerely,

/s/ Latham & Watkins LLP

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Corvus Pharmaceuticals, Inc. of our report dated March 28, 2023, relating to the financial statements, which appears in Corvus Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2022.

/s/ PricewaterhouseCoopers LLP  
San Jose, CA  
March 28, 2023

**Calculation of Filing Fee Tables**

**Form S-8**  
(Form Type)

**Corvus Pharmaceuticals, Inc.**  
(Exact Name of Registrant as Specified in its Charter)

**Table 1—Newly Registered Securities**

Security Type	Security Class Title	Fee Calculation Rule	Amount to be Registered <sup>(1)</sup>	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	Common stock, \$0.0001 par value per share	Rule 457(c) and Rule 457(h)	1,862,000 <sup>(2)</sup>	\$0.67 <sup>(3)</sup>	\$1,239,067.90	\$0.0001102	\$136.55
Total Offering Amounts					\$1,239,067.90		\$136.55
Total Fee Offsets <sup>(4)</sup>							\$ —
Net Fee Due							\$136.55

- (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of Corvus Pharmaceuticals, Inc.’s (the “Registrant”) common stock that become issuable under the 2016 Equity Incentive Award Plan (the “2016 Plan”) by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.
- (2) Represents the additional shares of common stock available for future issuance under the Registrant’s 2016 Plan resulting from an annual increase as of January 1, 2023.
- (3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price for shares reserved for future issuance under the 2016 Plan are based on the average of the high and the low price of Registrant’s Common Stock as reported on the Nasdaq Global Market on March 27, 2023, which was \$0.67.
- (4) The Registrant does not have any fee offsets.